\-\ Texto\\:\\ \ \(0\)\
\-\ temp\\ 100\\.8\\,\\ bp\\ 140\\/88\\,\\ hr\\ 70\\,\\ rr\\ 17\\.\\ \\ remainder\\ of\\ physical\\ exam\\ and\\ labs\\ were\\ unavailable\\.\ \(0\)\
\-\ the\\ prognosis\\ for\\ this\\ patient\\ is\\ poor\\.\\ \\ possible\\ therapies\\ are\\ palliative\\ chemotherapy\\ and\\ palliative\\ radiotherapy\\.\\ \\ the\\ pt\\ was\\ taken\\ to\\ the\\ special\\ procedures\\ lab\\ the\\ day\\ the\\ chest\\ film\\ was\\ read\\ by\\ a\\ radiologist\\ and\\ the\\ portion\\ of\\ the\\ catheter\\ was\\ removed\\ through\\ an\\ intravascular\\ approach\\.\ \(0\)\
\-\ study\\ from\\ december\\ demonstrates\\ increase\\ in\\ size\\ and\\ quantity\\ of\\ masses\\ over\\ all\\ lung\\ fields\\ as\\ compared\\ to\\ previous\\ study\\ of\\ august\\ in\\ the\\ same\\ year\\.\\ \\ largest\\ mass\\,\\ measuring\\ 3cm\\,\\ is\\ located\\ peripherally\\ in\\ the\\ left\\ lung\\ field\\.\\ \\ there\\ is\\ prominent\\ lymphadenopathy\\ in\\ both\\ hila\\.\\ \\ a\\ 9\\.5\\ cm\\ length\\ of\\ catheter\\ is\\ present\\ in\\ the\\ left\\ pulmonary\\ artery\\ and\\ extends\\ into\\ the\\ inferior\\ branch\\.\ \(0\)\
\-\ stage\\ iv\\ melanoma\ \(0\)\
\-\ migration\\ of\\ broken\\ catheter\ \(0\)\
\-\ mass\\ lesion\\:\ \(1\)\
\-\ granulomatous\\ disease\ \(29\)\
\-\ inflammation\ \(200\)\
\-\ benign\\ neoplasm\ \(14\)\
\-\ malignant\\ primary\ \(1\)\
\-\ metastatic\\ disease\ \(243\)\
\-\ congenital\\ abnormality\ \(6\)\
\-\ 52\\ y\\/o\\ woman\\ with\\ hx\\ of\\ resected\\ skin\\ lesion\\.\\ \\ had\\ latest\\ pa\\ and\\ lateral\\ done\\ as\\ part\\ of\\ a\\ fever\\ work\\ up\\,\\ with\\ prior\\ study\\ in\\ august\\ 2004\\ and\\ ct\\ in\\ november\\ 2004\\.\\ \\ past\\ surgical\\ history\\ consists\\ of\\ placement\\ of\\ a\\ port\\-a\\-cath\\.\ \(0\)\
\-\ complication\\ rates\\.\\ \\ next\\ to\\ skin\\,\\ subcutaneous\\ tissue\\,\\ and\\ lymph\\ nodes\\,\\ the\\ lungs\\ are\\ the\\ most\\ common\\ sites\\ of\\ melanoma\\ to\\ metastasize\\.\\ \\ this\\ is\\ thought\\ to\\ be\\ due\\ to\\ the\\ capillary\\ beds\\ in\\ the\\ lung\\ parenchyma\\.\\ \\ once\\ there\\ is\\ metastasis\\ to\\ the\\ lungs\\ or\\ other\\ distant\\ sites\\,\\ the\\ disease\\ is\\ stage\\ iv\\ and\\ has\\ a\\ 5\\-year\\ survival\\ of\\ 8\\-10\\%\\.\\ \\ placement\\ of\\ indwelling\\ catheters\\ is\\ not\\ without\\ complications\\.\\ \\ at\\ the\\ time\\ of\\ insertion\\ pneumothorax\\ is\\ a\\ known\\ complication\\.\\ \\ once\\ in\\ place\\ complications\\ include\\ infection\\,\\ thrombosis\\ with\\ possible\\ svc\\ syndrome\\,\\ erosion\\ of\\ svc\\,\\ pe\\ and\\ breakage\\ with\\ migration\\ as\\ in\\ this\\ case\\.\\ \\ migration\\ of\\ the\\ catheter\\ has\\ its\\ own\\ complications\\ to\\ include\\ pulmonary\\ infarctions\\,\\ pe\\,\\ perforation\\ and\\ arrhythmias\\.\ \(0\)\
\-\ up\\ to\\ date\\ \\â\\€\\“\\ imagining\\ studies\\ in\\ melanoma\ \(0\)\
\-\ harrison\\â\\€\\™s\\ principals\\ of\\ internal\\ medicine\\ 15th\\ ed\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ the\\:\\ 0\\.23149115053938527\ \(0\)\
\-\ catheter\\:\\ 0\\.21711142638297007\ \(0\)\
\-\ of\\:\\ 0\\.20313695782457677\ \(0\)\
\-\ migration\\:\\ 0\\.19368533770207913\ \(0\)\
\-\ melanoma\\:\\ 0\\.17106384721178938\ \(0\)\
\-\ in\\:\\ 0\\.16708806392785677\ \(0\)\
\-\ is\\:\\ 0\\.15049603182814555\ \(0\)\
\-\ complications\\:\\ 0\\.14029690401778008\ \(0\)\
\-\ and\\:\\ 0\\.13879102531698198\ \(0\)\
\-\ to\\:\\ 0\\.13738462276971294\ \(0\)\
\-\ svc\\:\\ 0\\.13662079047944567\ \(0\)\
\-\ august\\:\\ 0\\.13341957310222496\ \(0\)\
\-\ palliative\\:\\ 0\\.13170599632544472\ \(0\)\
\-\ study\\:\\ 0\\.12216848505454202\ \(0\)\
\-\ sites\\:\\ 0\\.11918357354566218\ \(0\)\
\-\ 2004\\:\\ 0\\.11502702703332789\ \(0\)\
\-\ once\\:\\ 0\\.11477663492765042\ \(0\)\
\-\ lung\\:\\ 0\\.11143108081033425\ \(0\)\
\-\ complication\\:\\ 0\\.11091497298103926\ \(0\)\
\-\ pe\\:\\ 0\\.10095717997694556\ \(0\)\
\-\ beds\\:\\ 0\\.09764873192508197\ \(0\)\
\-\ breakage\\:\\ 0\\.09764873192508197\ \(0\)\
\-\ principals\\:\\ 0\\.09764873192508197\ \(0\)\
\-\ stage\\:\\ 0\\.09725069726603357\ \(0\)\
\-\ placement\\:\\ 0\\.09536050432324492\ \(0\)\
\-\ imagining\\:\\ 0\\.09330857644281969\ \(0\)\
\-\ 15th\\:\\ 0\\.09330857644281969\ \(0\)\
\-\ skin\\:\\ 0\\.0908463142365927\ \(0\)\
\-\ lungs\\:\\ 0\\.09012596766755258\ \(0\)\
\-\ latest\\:\\ 0\\.08784062719852472\ \(0\)\
\-\ iv\\:\\ 0\\.08725745398929077\ \(0\)\
\-\ quantity\\:\\ 0\\.08588903163967138\ \(0\)\
\-\ harrison\\:\\ 0\\.08588903163967138\ \(0\)\
\-\ infarctions\\:\\ 0\\.08280964231878536\ \(0\)\
\-\ possible\\:\\ 0\\.08274352564156309\ \(0\)\
\-\ indwelling\\:\\ 0\\.08154887615740909\ \(0\)\
\-\ arrhythmias\\:\\ 0\\.08154887615740909\ \(0\)\
\-\ hila\\:\\ 0\\.07846948683652308\ \(0\)\
\-\ disease\\:\\ 0\\.07689284951248909\ \(0\)\
\-\ broken\\:\\ 0\\.07539009751563706\ \(0\)\
\-\ november\\:\\ 0\\.07474116304636952\ \(0\)\
\-\ metastasize\\:\\ 0\\.07474116304636952\ \(0\)\
\-\ catheters\\:\\ 0\\.07474116304636952\ \(0\)\
\-\ pulmonary\\:\\ 0\\.07443815037211934\ \(0\)\
\-\ december\\:\\ 0\\.07412933135426078\ \(0\)\
\-\ as\\:\\ 0\\.07359028327905884\ \(0\)\
\-\ include\\:\\ 0\\.07266065955930644\ \(0\)\
\-\ intravascular\\:\\ 0\\.0719813240371747\ \(0\)\
\-\ therapies\\:\\ 0\\.07150550612544809\ \(0\)\
\-\ special\\:\\ 0\\.0697891758719985\ \(0\)\
\-\ read\\:\\ 0\\.06939989149938836\ \(0\)\
\-\ own\\:\\ 0\\.06902426908203826\ \(0\)\
\-\ unavailable\\:\\ 0\\.0676411685549124\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.06613104341856091\ \(0\)\
\-\ peripherally\\:\\ 0\\.06480786226697352\ \(0\)\
\-\ capillary\\:\\ 0\\.06408596132229978\ \(0\)\
\-\ 3cm\\:\\ 0\\.06385575588013995\ \(0\)\
\-\ distant\\:\\ 0\\.06385575588013995\ \(0\)\
\-\ was\\:\\ 0\\.06384036988243137\ \(0\)\
\-\ rates\\:\\ 0\\.06363039723022645\ \(0\)\
\-\ radiologist\\:\\ 0\\.06298146276095892\ \(0\)\
\-\ this\\:\\ 0\\.0629442685366822\ \(0\)\
\-\ largest\\:\\ 0\\.062173219310617416\ \(0\)\
\-\ consists\\:\\ 0\\.060719580534863773\ \(0\)\
\-\ temp\\:\\ 0\\.06055100790934045\ \(0\)\
\-\ up\\:\\ 0\\.06040847112345586\ \(0\)\
\-\ fields\\:\\ 0\\.060060656199735205\ \(0\)\
\-\ procedures\\:\\ 0\\.05990207344007291\ \(0\)\
\-\ branch\\:\\ 0\\.05990207344007291\ \(0\)\
\-\ insertion\\:\\ 0\\.05990207344007291\ \(0\)\
\-\ survival\\:\\ 0\\.05959178677283109\ \(0\)\
\-\ approach\\:\\ 0\\.05857157321777768\ \(0\)\
\-\ lesion\\:\\ 0\\.05854734389715476\ \(0\)\
\-\ subcutaneous\\:\\ 0\\.05816244798593148\ \(0\)\
\-\ perforation\\:\\ 0\\.05764019121397776\ \(0\)\
\-\ field\\:\\ 0\\.05738831746382521\ \(0\)\
\-\ next\\:\\ 0\\.05702128240392979\ \(0\)\
\-\ erosion\\:\\ 0\\.056666416519151476\ \(0\)\
\-\ 52\\:\\ 0\\.05655069495431224\ \(0\)\
\-\ date\\:\\ 0\\.05643621107699164\ \(0\)\
\-\ rr\\:\\ 0\\.05609992769874902\ \(0\)\
\-\ resected\\:\\ 0\\.05588146826950179\ \(0\)\
\-\ has\\:\\ 0\\.055781142842903\ \(0\)\
\-\ length\\:\\ 0\\.05566737832311683\ \(0\)\
\-\ hx\\:\\ 0\\.05556191795781062\ \(0\)\
\-\ lab\\:\\ 0\\.05515016948358071\ \(0\)\
\-\ place\\:\\ 0\\.05504966038368178\ \(0\)\
\-\ part\\:\\ 0\\.054560801893091745\ \(0\)\
\-\ granulomatous\\:\\ 0\\.05427785659574252\ \(0\)\
\-\ medicine\\:\\ 0\\.05382229250366919\ \(0\)\
\-\ remainder\\:\\ 0\\.053733460952415706\ \(0\)\
\-\ prognosis\\:\\ 0\\.053733460952415706\ \(0\)\
\-\ pneumothorax\\:\\ 0\\.05321541757964771\ \(0\)\
\-\ thought\\:\\ 0\\.0527212925991639\ \(0\)\
\-\ hr\\:\\ 0\\.052482528636924604\ \(0\)\
\-\ removed\\:\\ 0\\.051870696944815865\ \(0\)\
\-\ nodes\\:\\ 0\\.051870696944815865\ \(0\)\
\-\ poor\\:\\ 0\\.051505332449183414\ \(0\)\
\-\ 70\\:\\ 0\\.05041351902520683\ \(0\)\
\-\ extends\\:\\ 0\\.05028455191702059\ \(0\)\
\-\ work\\:\\ 0\\.04978368204627382\ \(0\)\
\-\ thrombosis\\:\\ 0\\.04978368204627382\ \(0\)\
\-\ parenchyma\\:\\ 0\\.04960173760078149\ \(0\)\
\-\ bp\\:\\ 0\\.04954177027030997\ \(0\)\
\-\ compared\\:\\ 0\\.04936385802243934\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.04936385802243934\ \(0\)\
\-\ inflammation\\:\\ 0\\.04907375515846223\ \(0\)\
\-\ increase\\:\\ 0\\.049016666273843344\ \(0\)\
\-\ ed\\:\\ 0\\.048847204045951484\ \(0\)\
\-\ taken\\:\\ 0\\.048791307623929844\ \(0\)\
\-\ there\\:\\ 0\\.04859141737566635\ \(0\)\
\-\ done\\:\\ 0\\.048570595876843044\ \(0\)\
\-\ same\\:\\ 0\\.0483009559143246\ \(0\)\
\-\ located\\:\\ 0\\.0483009559143246\ \(0\)\
\-\ prominent\\:\\ 0\\.048090030065063814\ \(0\)\
\-\ with\\:\\ 0\\.047825489907875794\ \(0\)\
\-\ lymph\\:\\ 0\\.04748109961717752\ \(0\)\
\-\ measuring\\:\\ 0\\.04723725899347566\ \(0\)\
\-\ pa\\:\\ 0\\.04685831179259421\ \(0\)\
\-\ mass\\:\\ 0\\.04664681841063067\ \(0\)\
\-\ are\\:\\ 0\\.046339222874983356\ \(0\)\
\-\ previous\\:\\ 0\\.04613843450621049\ \(0\)\
\-\ film\\:\\ 0\\.04562861717841462\ \(0\)\
\-\ its\\:\\ 0\\.04518170010231614\ \(0\)\
\-\ studies\\:\\ 0\\.044790994668901636\ \(0\)\
\-\ metastasis\\:\\ 0\\.044752697166534475\ \(0\)\
\-\ abnormality\\:\\ 0\\.04441404936450875\ \(0\)\
\-\ pt\\:\\ 0\\.04394306365833853\ \(0\)\
\-\ congenital\\:\\ 0\\.043872409009116\ \(0\)\
\-\ portion\\:\\ 0\\.043663200906868954\ \(0\)\
\-\ malignant\\:\\ 0\\.0435259664567053\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.043356861194130986\ \(0\)\
\-\ labs\\:\\ 0\\.04230314482458146\ \(0\)\
\-\ benign\\:\\ 0\\.041944313219291034\ \(0\)\
\-\ neoplasm\\:\\ 0\\.041682869383124925\ \(0\)\
\-\ left\\:\\ 0\\.04165800836954742\ \(0\)\
\-\ masses\\:\\ 0\\.04156869080194095\ \(0\)\
\-\ inferior\\:\\ 0\\.04154033544630487\ \(0\)\
\-\ fever\\:\\ 0\\.041399674545835756\ \(0\)\
\-\ size\\:\\ 0\\.041343923688072104\ \(0\)\
\-\ internal\\:\\ 0\\.04115105107369474\ \(0\)\
\-\ past\\:\\ 0\\.03974563216377281\ \(0\)\
\-\ known\\:\\ 0\\.03953225352685371\ \(0\)\
\-\ day\\:\\ 0\\.03889437134611909\ \(0\)\
\-\ artery\\:\\ 0\\.03792251995387513\ \(0\)\
\-\ year\\:\\ 0\\.03763517203208084\ \(0\)\
\-\ primary\\:\\ 0\\.037545504765656754\ \(0\)\
\-\ infection\\:\\ 0\\.03688396168054738\ \(0\)\
\-\ syndrome\\:\\ 0\\.03681089559143245\ \(0\)\
\-\ through\\:\\ 0\\.03634774905199726\ \(0\)\
\-\ all\\:\\ 0\\.03634774905199726\ \(0\)\
\-\ time\\:\\ 0\\.03619198678138449\ \(0\)\
\-\ due\\:\\ 0\\.03509861150718361\ \(0\)\
\-\ cm\\:\\ 0\\.03506762989223191\ \(0\)\
\-\ common\\:\\ 0\\.034628190867974314\ \(0\)\
\-\ prior\\:\\ 0\\.03416335189403386\ \(0\)\
\-\ both\\:\\ 0\\.034050229145102494\ \(0\)\
\-\ over\\:\\ 0\\.03395221801763324\ \(0\)\
\-\ metastatic\\:\\ 0\\.03348852669663735\ \(0\)\
\-\ physical\\:\\ 0\\.03310830292062415\ \(0\)\
\-\ into\\:\\ 0\\.032458610770203004\ \(0\)\
\-\ chest\\:\\ 0\\.03223072690371379\ \(0\)\
\-\ without\\:\\ 0\\.032207018941656354\ \(0\)\
\-\ tissue\\:\\ 0\\.03203086344953652\ \(0\)\
\-\ woman\\:\\ 0\\.03180041018905927\ \(0\)\
\-\ most\\:\\ 0\\.03177763541346089\ \(0\)\
\-\ other\\:\\ 0\\.03170960039315104\ \(0\)\
\-\ were\\:\\ 0\\.031474826542970784\ \(0\)\
\-\ present\\:\\ 0\\.03133202932376062\ \(0\)\
\-\ exam\\:\\ 0\\.030737791654617187\ \(0\)\
\-\ demonstrates\\:\\ 0\\.030676036826638095\ \(0\)\
\-\ case\\:\\ 0\\.030676036826638095\ \(0\)\
\-\ had\\:\\ 0\\.03042249251222259\ \(0\)\
\-\ lateral\\:\\ 0\\.030302891932848\ \(0\)\
\-\ surgical\\:\\ 0\\.02967730347172951\ \(0\)\
\-\ by\\:\\ 0\\.025929749859016235\ \(0\)\
\-\ be\\:\\ 0\\.02476972756274952\ \(0\)\
\-\ from\\:\\ 0\\.024250567279895108\ \(0\)\
\-\ not\\:\\ 0\\.024105158746679067\ \(0\)\
\-\ an\\:\\ 0\\.02334925838593605\ \(0\)\
\-\ history\\:\\ 0\\.023328574050044328\ \(0\)\
\-\ ct\\:\\ 0\\.023246234101772154\ \(0\)\
\-\ at\\:\\ 0\\.023063252885443326\ \(0\)\
\-\ or\\:\\ 0\\.02124179531826625\ \(0\)\
\-\ patient\\:\\ 0\\.019859854230835312\ \(0\)\
\-\ for\\:\\ 0\\.01850691198077869\ \(0\)\
